Public equity report: Boundless to test IPO appetite as follow-ons continue to deliver

Jami Rubin’s arrival at Boundless last summer signaled that the biotech could be exploring a public offering. Now, the oncology start-up has entered the IPO queue, becoming the latest to test investors’ appetite as the industry looks for signs that conditions are improving for new listings.

San Diego-based Boundless Bio Inc. is developing oncology therapies that target extrachromosomal DNA. Its most advanced program is Chk1 inhibitor BBI-355, which is in the Phase I/II POTENTIATE study to treat oncogene-amplified cancers; preliminary efficacy and safety data are due next half...